{"url_path":"/sec/tsha/8-k/2026-06-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-276738-index.html","accession_number":"0001193125-26-276738","cik":"0001806310","ticker":"TSHA","issuer_name":"Taysha Gene Therapies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1806310/0001193125-26-276738-index.html","primary_entity_key":"0001806310","primary_entity_name":"Taysha Gene Therapies, Inc."},"word_count":92,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\n  \nExhibit Description\n\n99.1\n  \n[Press Release, dated June 22, 2026.](d20817dex991.htm)\n\n99.2\n  \n[Corporate Presentation, dated June 22, 2026.](d20817dex992.htm)\n\n104\n  \nCover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nTaysha Gene Therapies, Inc.\n\n \n\n \nBy:\n \n\n/s/ Kamran Alam\n\nDate: June 22, 2026\n \n\n \n\n \nKamran Alam\n\n \n\n \n\n \nChief Financial Officer"}